Veklury Approved to Treat COVID-19 in Younger Patient Population
April 25, 2022New Caplyta Dosage Strengths Approved
April 25, 2022April 25, 2022 – The U.S. FDA has approved Epsolay® (benzoyl peroxide, cream, 5%), from Sol-Gel Technologies, to treat inflammatory lesions of rosacea in adults.
- Epsolay uses a proprietary microencapsulation technology that slowly release benzoyl peroxide over time. It is the first benzoyl peroxide formulation FDA approved to treat rosacea.
- Under the recommended dosing, a pea-sized amount of Epsolay is applied once daily in a thin layer to each area of the face (forehead, chin, nose, and each cheek). Any unused Epsolay must be discarded 30 days after opening.
- Epsolay has launched at a wholesale acquisition cost (WAC) of $475 per 30g pump.